MET and non-small cell lung carcinoma: In 5 to 20% of patients’ resistance to EGFR treatment was associated with MET amplification, as was reported for therapy in CRC with antibodies [35] and in NSCLC for the kinase inhibitors erlotinib and gefitinib [36].